ARVO 2024

START-END May 5, 2024 from 3:45 PM to 4:00 PM PDT

Presentation Title: Safety, Tolerability, and Efficacy of Tinlarebant from the 24-Month Phase 2 study in Adolescent Patients Affected by Stargardt Disease
Presenting Author: Dr. John Grigg, MBBS
Presentation Number: 1026
Location: Tahoma 3 (Seattle Convention Center - Arch Building)

Supporting Materials

Join our mailing list.


Sign up to receive important updates and news from Belite Bio